“We were pleased to hear that 28 of our posters were accepted by ISPOR,” said Tim Wright, global president of Policy, Access, Value, and Evidence for Avalere Health. “ISPOR follows a stringent approval process and selecting posters of our research to appear in this year’s conference reinforces the quality and depth of our work.”

Additionally, of the 2,000 research posters that ISPOR will showcase in the Poster Gallery, two of our posters were selected for the ISPOR Poster Tour program. The exclusive tours feature high-impact abstracts within a specific topical category. Each poster tour is a 45-minute experience that leads attendees to the poster, enabling the presenter to provide a brief overview of the study and hold an interactive discussion.

Our team also presented a Theater Session on Monday May 6, providing insights on how to best establish value in today’s uncertain market. The presenters are all subject matter experts in policy, evidence and strategy, value, and market access.

“The session was designed to inform stakeholders how recent global policies, evolving stakeholder expectations, and a focus on sustained access have intensified requirements for demonstrating value,” noted Sarah Alwardt, US president of Policy, Access, Value, and Evidence for Avalere Health. “Our theater session acted as a dynamic discussion on how to create coherent value strategies.”

ISPOR is recognized globally as the leading professional society for health economics and outcomes research and for its role in improving healthcare decisions. ISPOR 2024 draws healthcare stakeholders with an interest in HEOR, including researchers and academicians, assessors and regulators, payers and policymakers, the life sciences industry, healthcare providers, and patient engagement organizations.

ISPOR anticipates nearly 5,000 attendees for this year’s conference. The following lists the Poster tours and Theater Session. For a list of the 28 posters showing at the Poster Gallery, visit us at Exhibit Booth 413.

Poster:   PT43

Title:           “How has real-world evidence been leveraged in non-oncology HTA submissions in the UK, France, and Germany?”

Time:          May 7, 3:30-4:15 PM (Registration is required.)